Post-Ischemic Treatment of Recombinant Human Secretory Leukocyte Protease Inhibitor (rhSLPI) Reduced Myocardial Ischemia/Reperfusion Injury

Myocardial ischemia/reperfusion (I/R) injury is a major cause of mortality and morbidity worldwide. Among factors contributing to I/R injury, proteolytic enzymes could also cause cellular injury, expand the injured area and induce inflammation, which then lead to cardiac dysfunction. Therefore, prot...

Descripció completa

Dades bibliogràfiques

Autors principals:	Podsawee Mongkolpathumrat, Anusak Kijtawornrat, Eakkapote Prompunt, Aussara Panya, Nipon Chattipakorn, Stephanie Barrère-Lemaire, Sarawut Kumphune
Format:	Artigo
Idioma:	Inglês
Publicat:	MDPI AG 2021-04-01
Col·lecció:	Biomedicines
Matèries:	ischemic heart disease ischemia/reperfusion injury secretory leukocyte protease inhibitor (SLPI) cardioprotection post-ischemic treatment
Accés en línia:	https://www.mdpi.com/2227-9059/9/4/422
Etiquetes:	Afegir etiqueta Sense etiquetes, Sigues el primer a etiquetar aquest registre!